STOCK TITAN
  1. Home
  2. News
  3. VRPX

Virpax Pharmaceuticals, Inc. - $VRPX STOCK NEWS

Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: $VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Virpax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Virpax Pharmaceuticals's position in the market.

News
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
Rhea-AI Summary
Virpax Pharmaceuticals extends CRADA with U.S. Army Institute of Surgical Research for Probudur
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
-
News
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
Rhea-AI Summary
Gerald W. Bruce appointed as President and CEO of Novvae Pharmaceuticals, Virpax's subsidiary focused on OTC pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
News
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
Rhea-AI Summary
Virpax Pharmaceuticals announces positive results for two pre-clinical Probudur dose escalation studies, showing three times longer efficacy than Exparel in the first study and four to five times longer effect in the second study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
News
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
Rhea-AI Summary
Virpax Pharmaceuticals will be presenting at the 16th annual Main Event on Tuesday, October 3rd at 12:00 PM PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Rhea-AI Summary
Altasciences chosen by Virpax Pharmaceuticals to conduct preclinical studies for their nanoparticle AnQlar™, which aims to prevent the spread of COVID-19 and influenza. Positive collaboration and progress reported by both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
-
News
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
Rhea-AI Summary
Virpax Pharmaceuticals forms subsidiary Novvae to focus on OTC pipeline, while Virpax focuses on Rx product pipeline. Novvae's first asset, AnQlar, demonstrated 24-hour anti-viral barrier activity against Influenza and Covid. Virpax in discussions for global rights of first refusal on two non-prescription assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
News
Virpax Pharmaceuticals Updates on Litigation
Rhea-AI Summary
Virpax Pharmaceuticals announces ruling on lawsuit filed by Scilex Pharmaceuticals and Sorrento Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
News
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. to present at H.C. Wainwright event, CEO giving presentation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
News
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced its financial results for Q2 2023. The company reported a decrease in general and administrative expenses and research and development expenses compared to the same period last year. The operating loss for Q2 2023 was $3.2 million. As of June 30, 2023, the company had $14.8 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
earnings
News
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
Stock VRPX logo
Virpax Pharmaceuticals, Inc.

Nasdaq:VRPX

VRPX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

VRPX Stock Data

2.53M
1.14M
25.72%
3.26%
2.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERWYN

About VRPX

virpax pharmaceuticals specializes in developing new drug delivery systems across various indications to increase compliance and maximize the ability to achieve full therapeutic efficacy. we develop branded pharmaceutical products for pain management by using cutting-edge technology to enhance patients'​ quality of life, all while creating value for our investors and partners. we are focused on becoming a global leader in non-opioid pain management by developing and delivering innovative pharmaceutical products to our customers. virpax is committed to collaborating with its network of u.s. and global partners to advance the development of proprietary drug platforms that will produce the next generation of branded pharmaceutical products.